Infectious Complications in Lupus Nephritis and Associated Factors: A Multicenter Study
- 1 Dalal Jamm Hospital, Dakar, Senegal
- 2 Dalal Jamm Hospital, Dakar, Senegal
- 3 Pikine Hospital, Dakar, Senegal
- 4 Dalal Jamm Hospital, Dakar, Senegal
Abstract
Introduction: The prevalence of infections in patients with systemic lupus erythematosus ranges from 26% to 78%. Patients with systemic lupus erythematosus are particularly susceptible to infections due to a dysfunction of immune response and the immunosuppressive therapy. Patients and method: We carried out this study with the aim of describing the prevalence of infections in lupus nephritis and determining the associated risk factors. This was a multi-center, observational, retrospective, descriptive and analytical study over a 10-year period from November 1, 2010 to October 31, 2020. The study was carried out in the nephrology departments of six hospitals in Dakar. Results: During the study period, 98 patients were included. The mean age was 32.32 ± 11.33 years with a sex ratio of 0.21. Among the included patients, fifty-four (55.1%) had at least one infectious episode, of which 53.7% had 1 infection, 24.1% had 2 infectious episodes and 22.2% had 3 infectious episodes. The overall incidence was 55.1 infections per 100 patient-years. 57.2% of these infectious episodes occurred within the first six months after the lupus was diagnosed. The main sites of infection were urinary (30.7%), gastrointestinal (22.0%) and pleuropulmonary (16.5%). The incriminated germ was a bacterium in 78.18% of cases, a virus in 5.46%, a parasite in 9.09 and a fungus in 7.27. The most frequently germ found was Escherichia coli (29.09%). The evolution was marked by recovery in 93.4% of cases. Deaths occurred in 15 patients of which 33.3% were related to infections. Factor significantly associated with the onset of infection in multivariate analysis was the presence of a proliferative class of lupus nephritis (p = 0.013). Conclusion: Infections were common during lupus nephritis. The presence of a proliferative class was risk factors for infection.
- Feldman, C.H., Hiraki, L.T., Winkelmayer, W.C., Marty, F.M., Franklin, J.M., Kim, S.C., et al. (2015) Serious Infections among Adult Medicaid Beneficiaries with Systemic Lupus Erythematosus and Lupus Nephritis. Arthritis & Rheumatology, 67, 1577-1585. https://doi.org/10.1002/art.39070
- Jallouli, M., Frigui, M., Marzouka, S., Maaloul, I., Kaddour, N. and Bahloul, Z. (2008) Infectious Complications in Systemic Lupus Erythematosus: A Series of 146 Patients. La Revue de Médecine Interne, 29, 626-631. https://doi.org/10.1016/j.revmed.2008.02.023
- Yap, D.Y.H., Tang, C.S.O., Ma, M.K.M., Lam, M.F. and Chan, T.M. (2012) Survival Analysis and Causes of Mortality in Patients with Lupus Nephritis. Nephrology Dialysis Transplantation, 27, 3248-3254. https://doi.org/10.1093/ndt/gfs073
- Ren, Y., Tang, J., Mok, M.Y., Chan, A.W., Wu, A. and Lau, C.S. (2003) Increased Apoptotic Neutrophils and Macrophages and Impaired Macrophage Phagocytic Clearance of Apoptotic Neutrophils in Systemic Lupus Erythematosus. Arthritis & Rheumatology, 48, 2888-2897. https://doi.org/10.1002/art.11237
- Herrinton, L.J., Liu, L., Goldfien, R., Alex Michaels, M. and Tran, T.N. (2016) Risk of Serious Infection for Patients with Systemic Lupus Erythematosus Starting Glucocorticoids with or without Antimalarials. The Journal of Rheumatology, 43, 1503-1509. https://doi.org/10.3899/jrheum.150671
- Yee, C.S., Su, L., Toescu, V., Hickman, R., Situnayake, D., Bowman, S., et al. (2015) Birmingham SLE Cohort: Outcomes of a Large Inception Cohort Followed for up to 21 Years. Rheumatology, 54, 836-843. https://doi.org/10.1093/rheumatology/keu412
- Lim, C.C., Liu, P.Y., Tan, H.Z., Lee, P., Chin, Y.M., Mok, I.Y.J., et al. (2017) Severe Infections in Patients with Lupus Nephritis Treated with Immunosuppressants: A Retrospective Cohort Study. Nephrology, 22, 478-484. https://doi.org/10.1111/nep.12809
- Houssiau, F.A., Vasconcelos, C., D’Cruz, D., et al. (2010) The 10-Year Follow-Up Data of the Euro-Lupus Nephritis Trial Comparing Low-Dose and High-Dose Intravenous Cyclophosphamide. Annals of the Rheumatic Diseases, 69, 61-64. https://doi.org/10.1136/ard.2008.102533
- Ibn Abdelouahab, A. (2020) Epidémiologie et facteurs de risque des infections au cours de la néphropathie lupique. Thèse de médecine. Université Mohammed V de Rabat, Rabat.
- Yin, P., Li, J., Wen, Q., Qiu, Y., Liang, W., Wang, J., et al. (2020) Infection-Related Hospitalization after Intensive Immunosuppressive Therapy among Lupus Nephritis and ANCA Glomerulonephritis Patients. Renal Failure, 42, 474-482. https://doi.org/10.1080/0886022X.2020.1763400